The latest cash-and-stock bid “substantially undervalues” Allergan and “creates significant risks and uncertainties” for its shareholders, the chief executive said in a letter.
via NYT > Business Day http://ift.tt/1pAC961
via WordPress http://ift.tt/1kXaHjp
via All Business Is Good Business http://ift.tt/1qnDBZl
Facts about monster energy Drinks 